Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer

Scientific Reports

Volumn 5, Issue , 2014, Pages

  Tan, Juan ^a   Yu, Chen Yang ^a   Wang, Zhen Hua ^a   Chen, Hao Yan ^a   Guan, Jian ^b   Chen, Ying Xuan ^a   Fang, Jing Yuan ^a  

^a School of Medicine   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL PHOSPHATE;

CASE CONTROL STUDY; ESOPHAGUS TUMOR; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; KIDNEY CARCINOMA; LUNG TUMOR; METABOLISM; NEOPLASM; PATHOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; STOMACH TUMOR;

CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INOSITOL PHOSPHATES; LOGISTIC MODELS; LUNG NEOPLASMS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84923327861     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08473     Document Type: Article

References (58)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90, doi:10.3322/ caac.20107 (2011).
2. Abnet, C. C. et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 42, 764-767, doi:10.1038/ng.649 (2010).
3. Landi, M. T. et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 85, 679-691, doi:10.1016/j.ajhg.2009.09.012 (2009).
4. Rothman, N. et al.A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42, 978-984, doi:10.1038/ng.687 (2010).
5. Maher, B. Personal genomes: The case of the missing heritability. Nature 456, 18-21, doi:10.1038/456018a (2008).
6. Yu, K. et al. Pathway analysis by adaptive combination of P-values. Genet Epidemiol 33, 700-709, doi:10.1002/gepi.20422 (2009).
7. Wang, K., Li, M. & Hakonarson, H. Analysing biological pathways in genomewide association studies. Nat Rev Genet 11, 843-854, doi:10.1038/nrg2884 (2010).
8. Hakim, S., Bertucci, M. C., Conduit, S. E., Vuong, D. L. & Mitchell, C. A. Inositol polyphosphate phosphatases in human disease. Curr Top Microbiol Immunol 362, 247-314, doi:10.1007/978-94-007-5025-8-12 (2012).
9. Vogt, P. K., Kang, S., Elsliger, M. A. & Gymnopoulos, M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32, 342-349, doi:10.1016/j.tibs.2007.05.005 (2007).
10. Bader, A. G., Kang, S., Zhao, L. & Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5, 921-929, doi:10.1038/nrc1753 (2005).
11. Hamilton, M. J. et al. Role of SHIP in cancer. Exp Hematol 39, 2-13, doi:10.1016/ j.exphem.2010.11.002 (2011).
12. Benjamin, D. I. et al. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. ACS Chem Biol 9, 1340-1350, doi:10.1021/cb5001907 (2014).
13. Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61, doi:10.1016/j.cell.2009.11.027 (2010).
14. Chiang, K. P.,Niessen, S., Saghatelian, A.&Cravatt, B. F.An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem Biol 13, 1041-1050, doi:10.1016/j.chembiol.2006.08.008 (2006).
15. Koutros, S. et al. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res 70, 2389-2396, doi:10.1158/0008- 5472.CAN-09-3575 (2010).
16. Yang, Y. C. et al. Genetic polymorphisms in the ITPKC gene and cervical squamous cell carcinoma risk. Cancer Immunol Immunother 61, 2153-2159, doi:10.1007/s00262-012-1280-y (2012).
17. Haiman, C. A. et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev 15, 1021-1025, doi:10.1158/1055-9965.EPI-05-0896 (2006).
18. Karakas, B. et al. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biol Ther 14, 888-896, doi:10.4161/cbt.25945 (2013).
19. Stjernstrom, A. et al. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med 3, 337-348, doi:10.1002/cam4.191 (2014).
20. Hao, N. B. et al. PLCE1 polymorphism and upper gastrointestinal cancer risk: a meta-analysis. PLoS One 8, e67229, doi:10.1371/journal.pone.0067229 (2013).
21. Jing, F. et al. The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population. Tumour Biol 35, 9233-9240, doi:10.1007/s13277-014- 2197-1 (2014).
22. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3- kinases as regulators of growth and metabolism. Nat Rev Genet 7, 606-619, doi:10.1038/nrg1879 (2006).
23. McCrea, H. J. & De Camilli, P. Mutations in phosphoinositide metabolizing enzymes and human disease. Physiology (Bethesda) 24, 8-16, doi:10.1152/ physiol.00035.2008 (2009).
24. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554, doi:10.1126/science.1096502 (2004).
25. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11, 329-341, doi:10.1038/nrm2882 (2010).
26. Hyland, P. L. et al. Genetic variants in fas signaling pathway genes and risk of gastric cancer. Int J Cancer 134, 822-831, doi:10.1002/ijc.28415 (2014).
27. Li, W. Q. et al.Genetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population. PLoS One 8, e68999, doi:10.1371/journal.pone.0068999 (2013).
28. Li, W. Q. et al. Genetic variants in DNA repair pathway genes and risk of esophageal squamous cell carcinoma and gastric adenocarcinoma in a Chinese population. Carcinogenesis 34, 1536-1542, doi:10.1093/carcin/bgt094 (2013).
29. Lee, D., Lee, G. K., Yoon, K. A. & Lee, J. S. Pathway-based analysis using genomewide association data from aKorean non-small cell lung cancer study. PLoS One 8, e65396, doi:10.1371/journal.pone.0065396 (2013).
30. Menashe, I. et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res 70, 4453-4459, doi:10.1158/0008-5472.can-09-4502 (2010).
31. Menashe, I. et al. Large-scale pathway-based analysis of bladder cancer genomewide association data from five studies of European background. PLoS One 7, e29396, doi:10.1371/journal.pone.0029396 (2012).
32. Wei, P., Tang, H. & Li, D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. PLoS One 7, e46887, doi:10.1371/ journal.pone.0046887 (2012).
33. Jia, P., Liu, Y. & Zhao, Z. Integrative pathway analysis of genome-wide association studies and gene expression data in prostate cancer. BMC Syst Biol 6 Suppl 3, S13, doi:10.1186/1752-0509-6-S3-S13 (2012).
34. Friedrich, F. W. et al. A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J 30, 1648-1655, doi:10.1093/eurheartj/ehp153 (2009).
35. Wang, X. et al. Screening of new tumor suppressor genes in sporadic colorectal cancer patients. Hepatogastroenterology 55, 2039-2044 (2008).
36. Luo, X. P. Phospholipase C epsilon-1 inhibits p53 expression in lung cancer. Cell Biochem Funct 32, 294-298, doi:10.1002/cbf.3015 (2014).
37. Ou, L. et al. RNA interference suppressing PLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line. Cancer Genet Cytogenet 200, 110-119, doi:10.1016/j.cancergencyto.2010.01.021 (2010).
38. Bai, Y. et al. Crucial role of phospholipase Cepsilon in chemical carcinogeninduced skin tumor development. Cancer Res 64, 8808-8810, doi:10.1158/0008- 5472.can-04-3143 (2004).
39. Kim, J. K. et al. Subtype-specific roles of phospholipase C-beta via differential interactions with PDZ domain proteins. Adv Enzyme Regul 51, 138-151, doi:10.1016/j.advenzreg.2010.10.004 (2011).
40. Cocco, L. et al. Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells. Adv Enzyme Regul 47, 2-9, doi:10.1016/j.advenzreg.2006.12.003 (2007).
41. Guerrero-Preston, R. et al. Key tumor suppressor genes inactivated by ''greater promoter'' methylation and somatic mutations in head and neck cancer. Epigenetics 9, 1031-1046, doi:10.4161/epi.29025 (2014).
42. Danielsen, S. A. et al. Phospholipase C isozymes are deregulated in colorectal cancer-insights gained from gene set enrichment analysis of the transcriptome. PLoS One 6, e24419, doi:10.1371/journal.pone.0024419 (2011).
43. Fu, L. et al. Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res 67, 10720-10726, doi:10.1158/0008-5472.CAN-07-2411 (2007).
44. Hu, X. T. et al. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene 28, 2466-2475, doi:10.1038/onc.2009.92 (2009).
45. Xiang, T. et al. PLCD1 is a functional tumor suppressor inducing G(2)/M arrest and frequently methylated in breast cancer. Cancer Biol Ther 10, 520-527, doi:10.4161/cbt.10.5.12726 (2010).
46. Stallings, J. D., Zeng, Y. X., Narvaez, F. & Rebecchi, M. J. Phospholipase C-delta1 expression is linked to proliferation, DNA synthesis, and cyclin E levels. J Biol Chem 283, 13992-14001, doi:10.1074/jbc.M800752200 (2008).
47. Maffucci, T. et al. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 169, 789-799, doi:10.1083/jcb.200408005 (2005).
48. Katso, R. M. et al. Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 17, 3729-3744, doi:10.1091/mbc.E05-11-1083 (2006).
49. Hung, C. S., Lin, Y. L.,Wu, C. I., Huang, C. J. & Ting, L. P. Suppression of hepatitis B viral gene expression by phosphoinositide 5-phosphatase SKIP. Cell Microbiol 11, 37-50, doi:10.1111/j.1462-5822.2008.01235.x (2009).
50. Ijuin, T. & Takenawa, T. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. Mol Cell Biol 23, 1209-1220 (2003).
51. Ijuin, T. & Takenawa, T. Regulation of insulin signaling by the phosphatidylinositol 3,4,5-triphosphate phosphatase SKIP through the scaffolding function of Pak1. Mol Cell Biol 32, 3570-3584, doi:10.1128/ MCB.00636-12 (2012).
52. Hyland, P. L. et al. Genetic variants in sex hormone metabolic pathway genes and risk of esophageal squamous cell carcinoma. Carcinogenesis 34, 1062-1068, doi:10.1093/carcin/bgt030 (2013).
53. Li, D. et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 33, 1384-1390, doi:10.1093/carcin/bgs151 (2012).
54. Purdue, M. P. et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43, 60-65, doi:10.1038/ng.723 (2011).
55. Petersen, G. M. et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 42, 224-228, doi:10.1038/ng.522 (2010).
56. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39, 645-649, doi:10.1038/ng2022 (2007).
57. Hunter, D. J. et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39, 870-874, doi:10.1038/ng2075 (2007).
58. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38, 904-909, doi:10.1038/ng1847 (2006).